Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07828002) titled 'The GranStone Trial' on Sept. 11.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
Primary Sponsor: Martin Blomberg Jensen
Condition:
Paraffinoma
Granuloma, Foreign-Body
Intervention:
Drug: empagliflozin (Jardiance) 25 mg
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: September 2026
Target Sample Size: 100
Countries of Recruitment:
Denmark
To know more, visit https://clinicaltrials.gov/study/NCT07828002
Disclaimer: Curated by HT Syndication....